US AND Europe Diabetes Associated Eye Disorders Market Research Report Forecast to 2030

US AND Europe Diabetes Associated Eye Disorders Market is expected to register a notable CAGR of 6.46% during the review period. Diabetes-Associated Eye Disorders, also known as Diabetic Eye Diseases, refer to a group of eye conditions that can develop as complications of diabetes, particularly in individuals who have poorly managed blood sugar levels over an extended period.

The market growth is attributed to the rising prevalence of Diabetis, increasing awareness of opthalmic diseases, and growing government initiatives.

Market Segmentation

Based on disease type, the US and Europe diabetes associated eye disorders market has been bifurcated into diabetic retinopathy and Diabetic Macular Edema (DME). The diabetic retinopathy segment dominated the market in 2022, while the diabetic macular edema (DME) segment is projected to be the faster-growing segment during the forecast period, 2023-2032.

On the basis of diagnosis & treatment, the US and Europe diabetes associated eye disorders market is bifurcated into diagnosis and treatment. The treatment segment dominated the market in 2022, as well as treatment segment is projected to be the faster-growing segment during the forecast period, 2023-2032.

On the basis of end user, the US and Europe diabetes associated eye disorders market is segmented into hospitals & clinics, ophthalmic centers, and others. The hospitals & clinics segment dominated the market in 2022, while the ophthalmic centers segment is projected to be the fastest-growing segment during the forecast period, 2023-2032.

Regional Analysis

The report on the US and Europe diabetes associated eye disorders market has been segmented based on Country/ Region as US, Europe

The US dominated the market for diabetes associated eye disorders in 2022, accounting for the largest revenue share of 52.82%. Strong healthcare infrastructure, rising patient awareness of early disease diagnosis and treatment, supportive reimbursement policies, and the rising prevalence of diabetes are some of the main causes of the region's growth. Diabetes is on the rise in the United States at an alarming rate.

Government initiatives, an extensive number of R&D activities, and the improvement of healthcare providers' skill sets are factors that promote growth in the diabetes associated eye disorder market. When combined with patients' increasing awareness, it is anticipated that such supportive initiatives will result in profitable growth. By utilizing cutting-edge technology and using laser procedures with quick recoveries, the treatment of diabetic associated eye disorder market is anticipated to increase patient willingness for treatment.

Major Players

Thes include Novartis AG, Carl Zeiss Meditec AG, Alimera Sciences, Topcon Corporation, Bayer AG, and Regeneron Pharmaceuticals Inc.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 INTRODUCTION
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE Error! Bookmark not defined.
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF DIABETES
- 4.2.2 RISE IN GOVERNMENT INITIATIVES
4.3 RESTRAINTS
- 4.3.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS
4.4 OPPORTUNITY
- 4.4.1 GROWING NUMBER OF KEY PLAYERS AND APPROVAL OF TREATMENT

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 COVID-19 IMPACT ANALYSIS
- 5.3.1 OVERVIEW
5.4 PREMIUM INSIGHTS
- 5.4.1 ANTI-VEGF FAILURES
- 5.4.2 IMPACT OF AI IN RETINAL SCREENING
- 5.4.3 LIMITATIONS DUE TO DEARTH OF OPHTHALMOLOGY MD SPECIALISTS

6 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE

6.1 INTRODUCTION
6.2 DIABETIC RETINOPATHY
- 6.2.1 MILD NONPROLIFERATIVE STAGE
- 6.2.2 MODERATE NONPROLIFERATIVE STAGE
- 6.2.3 SEVERE NONPROLIFERATIVE STAGE
- 6.2.4 PROLIFERATIVE DIABETIC
6.3 DIABETIC MACULAR EDEMA (DME)

7 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE & TREATMENT

7.1 INTRODUCTION
7.2 DIAGNOSIS
- 7.2.1 FLUORESCEIN ANGIOGRAPHY
- 7.2.2 OPTICAL COHERENCE TOMOGRAPHY (OCT)
- 7.2.3 OPHTHALMOSCOPY
- 7.2.4 SLIT LAMP BIOMICROSCOPY
- 7.2.5 OTHERS
7.3 TREATMENT
- 7.3.1 ANTI-VEGF
- 7.3.2 INTRAOCULAR STEROID INJECTION
- 7.3.3 LASER SURGERY
- 7.3.4 VITRECTOMY

8 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER

8.1 INTRODUCTION
8.2 HOSPITAL & CLINICS
8.3 OPHTHALMIC CENTERS
8.4 OTHERS

9 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY REGION

9.1 INTRODUCTION
9.2 US
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2022
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 10.6.2 MERGER AND ACQUISITION
- 10.6.3 PARTNERSHIP/INVESTMENT

11 COMPANY PROFILES

11.1 NOVARTIS AG
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGY
11.2 GENENTECH, INC.
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGY
11.3 CARL ZEISS MEDITEC AG
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
11.4 DIGITAL DIAGNOSTICS, INC.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
11.5 BAYER AG
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
11.6 REGENERON PHARMACEUTICALS INC
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 AMPIO PHARMACEUTICALS INC
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 KEY STRATEGIES
11.8 TOPCON CORPORATION
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 DISEASE TYPES OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGY
11.9 ALIMERA SCIENCES
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGY
11.10 GEUDER AG
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGY

12 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 33
TABLE 2 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 51
TABLE 3 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY REGION, 2019-2032 (USD MILLION) 51
TABLE 4 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 51
TABLE 5 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR MILD NONPROLIFERATIVE STAGE, BY REGION, 2019-2032 (USD MILLION) 52
TABLE 6 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR MODERATE NONPROLIFERATIVE STAGE, BY REGION, 2019-2032 (USD MILLION) 52
TABLE 7 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR SEVERE NONPROLIFERATIVE STAGE, BY REGION, 2019-2032 (USD MILLION) 52
TABLE 8 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR PROLIFERATIVE DIABETIC, BY REGION, 2019-2032 (USD MILLION) 53
TABLE 9 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC MACULAR EDEMA (DME), BY REGION, 2019-2032 (USD MILLION) 53
TABLE 10 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 56
TABLE 11 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY REGION, 2019-2032 (USD MILLION) 56
TABLE 12 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 57
TABLE 13 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR FLUORESCEIN ANGIOGRAPHY, BY REGION, 2019-2032 (USD MILLION) 57
TABLE 14 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OPTICAL COHERENCE TOMOGRAPHY (OCT), BY REGION, 2019-2032 (USD MILLION) 57
TABLE 15 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OPHTHALMOSCOPY, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 16 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR SLIT LAMP BIOMICROSCOPY, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 17 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION) 58
TABLE 18 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY REGION, 2019-2032 (USD MILLION) 59
TABLE 19 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 59
TABLE 20 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR ANTI-VEGF, BY REGION, 2019-2032 (USD MILLION) 59
TABLE 21 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR INTRAOCULAR STEROID INJECTION, BY REGION, 2019-2032 (USD MILLION) 60
TABLE 22 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR LASER SURGERY, BY REGION, 2019-2032 (USD MILLION) 60
TABLE 23 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR VITRECTOMY, BY REGION, 2019-2032 (USD MILLION) 60
TABLE 24 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 62
TABLE 25 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2019-2032 (USD MILLION) 63
TABLE 26 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OPHTHALMIC CENTERS, BY REGION, 2019-2032 (USD MILLION) 63
TABLE 27 US AND EUROPE: DIABETIC ASSOCIATED EYE DISORDERS MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION) 63
TABLE 28 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDER MARKET, BY REGION, 2019-2032 (USD MILLION) 65
TABLE 29 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 66
TABLE 30 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 66
TABLE 31 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 66
TABLE 32 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 67
TABLE 33 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 67
TABLE 34 US: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER 2019-2032 (USD MILLION) 67
TABLE 35 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 69
TABLE 36 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 70
TABLE 37 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 70
TABLE 38 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 70
TABLE 39 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 71
TABLE 40 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 71
TABLE 41 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 71
TABLE 42 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 72
TABLE 43 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 72
TABLE 44 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 72
TABLE 45 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 73
TABLE 46 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 73
TABLE 47 GERMANY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 73
TABLE 48 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 74
TABLE 49 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 74
TABLE 50 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 74
TABLE 51 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 75
TABLE 52 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 75
TABLE 53 FRANCE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 75
TABLE 54 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 76
TABLE 55 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 76
TABLE 56 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 76
TABLE 57 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 77
TABLE 58 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 77
TABLE 59 UK: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 77
TABLE 60 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 78
TABLE 61 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 78
TABLE 62 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 78
TABLE 63 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 79
TABLE 64 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 79
TABLE 65 ITALY: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 79
TABLE 66 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 80
TABLE 67 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 80
TABLE 68 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 80
TABLE 69 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 81
TABLE 70 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 81
TABLE 71 SPAIN: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 81
TABLE 72 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2019-2032 (USD MILLION) 82
TABLE 73 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIABETIC RETINOPATHY, BY TYPE, 2019-2032 (USD MILLION) 82
TABLE 74 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 82
TABLE 75 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 83
TABLE 76 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD MILLION) 83
TABLE 77 REST OF EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2019-2032 (USD MILLION) 83
TABLE 78 PUBLIC PLAYERS STOCK SUMMARY 87
TABLE 79 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 87
TABLE 80 PRODUCT LAUNCH/PRODUCT APPROVAL 88
TABLE 81 MERGER AND ACQUISITION 88
TABLE 82 PARTNERSHIP/INVESTMENT 89
TABLE 83 NOVARTIS AG: PRODCUTS OFFERED 91
TABLE 84 NOVARTIS AG: KEY DEVELOPMENTS 92
TABLE 85 GENENTECH, INC.: PRODUCTS OFFERED 93
TABLE 86 GENENTECH, INC.: KEY DEVELOPMENTS 94
TABLE 87 CARL ZEISS MEDITEC AG: PRODUCTS OFFERED 96
TABLE 88 CARL ZEISS MEDITEC AG: KEY DEVELOPMENTS 97
TABLE 89 DIGITAL DIAGNOSTICS, INC. : PRODUCTS OFFERED 99
TABLE 90 DIGITAL DIAGNOSTICS, INC. : KEY DEVELOPMENTS 100
TABLE 91 BAYER AG: PRODCUTS OFFERED 102
TABLE 92 REGENERON PHARMACEUTICALS INC: PRODCUTS OFFERED 105
TABLE 93 REGENERON PHARMACEUTICALS INC: KEY DEVELOPMENTS 106
TABLE 94 AMPIO PHARMACEUTICALS INC: PRODCUTS OFFERED 108
TABLE 95 TOPCON CORPORATION: DISEASE TREATMENT OFFERED 112
TABLE 96 TOPCON CORPORATION: KEY DEVELOPMENTS 112
TABLE 97 ALIMERA SCIENCES: PRODCUTS OFFERED 115
TABLE 98 ALIMERA SCIENCES: KEY DEVELOPMENTS 116
TABLE 99 GEUDER AG: PRODCUTS OFFERED 117

LIST OF FIGURES

FIGURE 1 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET: STRUCTURE 20
FIGURE 2 US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 36
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 38
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 39
FIGURE 5 OPPORTUNITY IMPACT FORECAST 40
FIGURE 6 VALUE CHAIN ANALYSIS: US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET 41
FIGURE 7 PORTER'S FIVE FORCES MODEL: US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET 43
FIGURE 8 US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET; DISEASE TYPE SEGMENT ATTRACTIVENESS, (USD MILLION) 49
FIGURE 9 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE, 2022 & 2032 (USD MILLION) 50
FIGURE 10 US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET; DIAGNOSIS & TREATMENT SEGMENT ATTRACTIVENESS, (USD MILLION) 55
FIGURE 11 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY DIAGNOSIS & TREATMENT, 2022 & 2032 (USD MILLION) 55
FIGURE 12 US AND EUROPE DIABETES ASSOCIATED EYE DISORDERS MARKET; END USER SEGMENT ATTRACTIVENESS, (USD MILLION) 61
FIGURE 13 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDERS MARKET, BY END USER, 2022 & 2032 (USD MILLION) 62
FIGURE 14 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDER MARKET SHARE, BY REGION, 2022 (% SHARE) 64
FIGURE 15 US AND EUROPE DIABETIC ASSOCIATED EYE DISORDER MARKET, BY REGION, 2022 & 2030 (USD MILLION) 64
FIGURE 16 US MARKET ANALYSIS: DIABETES ASSOCIATED EYE DISORDERS MARKET, 2019-2023(USD MILLION) 65
FIGURE 17 EUROPE MARKET ANALYSIS: DIABETES ASSOCIATED EYE DISORDERS MARKET, 2019-2023 (USD MILLION) 68
FIGURE 18 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET SHARE, BY COUNTRY, 2022 (% SHARE) 69
FIGURE 19 EUROPE: DIABETES ASSOCIATED EYE DISORDERS MARKET, BY COUNTRY, 2022 & 2030 (USD MILLION) 69
FIGURE 20 US AND EU DIABETES ASSOCIATED EYE DISORDERS PLAYERS: COMPETITIVE ANALSIS, 2022 85
FIGURE 21 COMPETITOR DASHBOARD: US AND EU DIABETES ASSOCIATED EYE DISORDERS 86
FIGURE 22 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 91
FIGURE 23 NOVARTIS AG: SWOT ANALYSIS 92
FIGURE 24 GENENTECH, INC.: SWOT ANALYSIS 94
FIGURE 25 CARL ZEISS MEDITEC AG: FINANCIAL OVERVIEW SNAPSHOT 96
FIGURE 26 CARL ZEISS MEDITEC AG: SWOT ANALYSIS 98
FIGURE 27 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 102
FIGURE 28 BAYER AG: SWOT ANALYSIS 103
FIGURE 29 REGENERON PHARMACEUTICALS INC: FINANCIAL OVERVIEW SNAPSHOT 105
FIGURE 30 REGENERON PHARMACEUTICALS INC: SWOT ANALYSIS 106
FIGURE 31 TOPCON CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 111
FIGURE 32 TOPCON CORPORATION: SWOT ANALYSIS 113
FIGURE 33 ALIMERA SCIENCES: FINANCIAL OVERVIEW SNAPSHOT 115